Hester Biosciences Ltd

Hester Biosciences Ltd: Trading Window closed from 1 October 2026; ends 48 hours after the financial results for the quarter and six months ended 30 September 2026 become generally available.

Rating action & outlook

• Long-term bank facilities upgraded to BBB+; Stable outlook.
• Long-term/short-term facilities upgraded to BBB+ / A2; Stable outlook.
• Short-term bank facilities upgraded to A2; Stable outlook.

Facilities & ratings

• Long-term facilities: Rs 48.45 crore; upgraded to BBB+; Stable.
• Long-term/short-term facilities: Rs 65.00 crore; BBB+ / A2; Stable.
• Short-term facilities: Rs 0.22 crore; A2; Stable.
• Total facilities: Rs 113.67 crore.

Rationale & material changes

• Upgrade reflects improved FY26 and Q1FY27 performance.
• Strengthening financial profile and liquidity evident; leverage remains a consideration.
• Outlook remains Stable for all upgraded ratings.
• Last rating upgraded from BBB to BBB+ and A3+ to A2 for some facilities.

Annual report microsite launch

• Launch of dedicated digital microsite for the 39th Annual Report FY 2025-26.
• Microsite offers mobile-friendly navigation and interactive presentation of financial, operational and strategic highlights.
• Includes download and sharing options to improve accessibility and stakeholder engagement.
• Initiative supports digital transformation, sustainability and transparent stakeholder communication.
• Accessible at https://annualreport.hester.in/.

Meeting Details

• Audio recording of the earnings conference call for the quarter ended 30 June 2026 is available.

Purpose

• Discuss quarterly earnings results for the quarter ended 30 June 2026.

Board approvals and filing

• Board approved unaudited standalone and consolidated Q1 FY27 results for quarter ended 30 June 2026.
• Results and limited review reports attached; press release issued; newspaper extract to be published.
• Board meeting commenced 10:30 a.m. and concluded 11:07 a.m. IST.

Standalone highlights

• Standalone revenue 726.60 million.
• Standalone gross margin 78%, up from 69%.
• Standalone EBITDA 260.34 million; margin 36%.
• Standalone PAT 147.11 million; margin 20%.
• Standalone EPS 17.29 INR.

Consolidated highlights

• Consolidated revenue 772.44 million; down 8% YoY.
• Consolidated gross margin 78%; up from 73%.
• Consolidated EBITDA 1,118.06 million; margin 145%.
• Consolidated PAT 967.32 million; margin 125%.
• Exceptional gain from Gates Foundation loan amendment: INR 853.49 million.

Outlook and strategic focus

• Nepal and Africa revenues lower due to timing of orders.
• Long-term focus on strengthening biologicals portfolio and expanding domestic and export markets.
• Continued investments in R&D and regulatory submissions.

Financial results approved

• Board approved unaudited standalone and consolidated results for quarter ended 30 June 2026.

Disclosures and reports

• Limited review reports and press release attached; newspaper extracts to be published per SEBI LODR.

Notable item

• Consolidated results include exceptional gain of INR 853.49 million from Gates Foundation loan amendment (HBAL).

Meeting Details

• Date and time: Thursday, 30 July 2026 at 2:00 p.m. IST.
• Type and mode: teleconference group investor call following financial results.
• Event/organiser: Q1FY27 Results Conference Call by Hester Biosciences Limited.
• Purpose: earnings/results discussion and investor interaction.
• Key participants: CEO & Managing Director, Executive Director, Chief Financial Officer.
• Joining details: joining information attached in the notice.

Promoter reclassification update

• NSE and BSE approved reclassification of Ravin Gandhi and Bela Gandhi from Promoter Group to Public.
• Approvals issued on 24 July 2026.
• Reclassification under Regulation 31A of SEBI LODR.
• Earlier related submissions dated 15 May 2026 and 20 May 2026 referenced.
• Company to file subsequent disclosures for material events under Regulation 31A.
• No financial implications disclosed.

Disposal of TLPL equity stake

• Transferred remaining 543,248 TLPL shares (11%) on 8 July 2026.
• Aggregate consideration: INR 23 million.
• Holding in TLPL reduced from 11% to nil.
• Transferees: existing TLPL shareholders per Board-approved terms.
• Disclosure under Regulation 30 of SEBI LODR.